AHA: Methamphetamine-Related Heart Failure on the Rise
TUESDAY, Nov. 14, 2017 -- Heart failure due to methamphetamine use is increasing in prevalence among U.S. veterans, according to a study presented at the American Heart Association's Scientific Sessions, being held Nov. 11 to 15 in Anaheim, California.
Marin Nishimura, M.D., from the University of California, San Diego, and colleagues assessed the risk of heart failure due to methamphetamine use among 9,588 patients with a diagnosis of heart failure treated at San Diego Veterans Affairs Medical Center between 2005 and 2015. ICD-9 codes identified 480 of the patients as having a known history of methamphetamine abuse.
The researchers found that over the study period, the prevalence of methamphetamine usage among patients with heart failure increased linearly. A preliminary cohort comparison showed that patients with heart failure due to methamphetamine use had similar ejection fraction and B-type natriuretic peptide levels compared with those without methamphetamine use but trends toward increased troponin levels, more atrial fibrillation, and a higher glomerular filtration rate. Patients with heart failure due to methamphetamine also had a greater risk of emergency room visits (2.3 versus 0.5 per year; P = 0.01) and a trend toward a greater risk of all-cause hospital readmission (1.3 versus 0.6 per year; P = 0.09).
"In addition to other health problems associated with the drug, clinicians are seeing more heart failure with meth use, suggesting heart failure due to methamphetamine use could be a new epidemic," Nishimura said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: November 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.